Skip to main content
Premium Trial:

Request an Annual Quote

Is It Useful?

In an editorial, the New York Times warns that even though 23andMe has health risk tests that have gotten US Food and Drug Administration clearance, it does not mean the tests will be useful.

Last month, 23andMe announced it had gotten clearance for a genetic test for a syndrome associated with an increased risk of colorectal cancer and, last March, it received clearance for its test of three BRCA1 and BRCA2 mutations. Previously, the firm also received clearance for its Bloom syndrome test.

The Times notes, though, that 23andMe's tests are often simpler than clinical genetic tests, and such as in the case of its BRCA test, only examines small sections of those genes. That means, it adds, that the test doesn't capture all the variants in those genes that could contribute to disease risk. The Times adds that 23andMe informs users of the tests' limitations, but it says that the "tests are still more parlor trick than medicine."

At his Genomics, Medicine, and Pseudoscience blog, Johns Hopkins University's Steven Salzberg writes that the Times in that last bit is incorrect, adding that 23andMe's assay is accurate and validated and that the company warns users about its limitations. "It's legitimate to argue that you won't learn anything useful from the 23andMe tests, but you will learn something about genetics," he adds.

The Scan

Study Links Evolution of Longevity, Social Organization in Mammals

With the help of comparative phylogenetics and transcriptomics, researchers in Nature Communications see ties between lifespan and social organization in mammals.

Tumor Microenvironment Immune Score Provides Immunotherapy Response, Prognostic Insights

Using multiple in situ analyses and RNA sequence data, researchers in eBioMedicine have developed a score associated with immunotherapy response or survival.

CRISPR-Based Method for Finding Cancer-Associated Exosomal MicroRNAs in Blood

A team from China presents in ACS Sensors a liposome-mediated membrane fusion strategy for detecting miRNAs carried in exosomes in the blood with a CRISPR-mediated reporter system.

Drug Response Variants May Be Distinct in Somatic, Germline Samples

Based on variants from across 21 drug response genes, researchers in The Pharmacogenomics Journal suspect that tumor-only DNA sequences may miss drug response clues found in the germline.